Sysmex (OTCMKTS:SSMXY – Get Free Report) and iRadimed (NASDAQ:IRMD – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.
Risk & Volatility
Sysmex has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, iRadimed has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.
Dividends
Sysmex pays an annual dividend of $0.14 per share and has a dividend yield of 1.6%. iRadimed pays an annual dividend of $0.80 per share and has a dividend yield of 0.9%. Sysmex pays out 36.8% of its earnings in the form of a dividend. iRadimed pays out 43.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. iRadimed has increased its dividend for 1 consecutive years. Sysmex is clearly the better dividend stock, given its higher yield and lower payout ratio.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sysmex | $3.32 billion | 1.67 | $235.54 million | $0.38 | 23.18 |
| iRadimed | $83.81 million | 14.04 | $22.48 million | $1.83 | 50.33 |
Sysmex has higher revenue and earnings than iRadimed. Sysmex is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
92.3% of iRadimed shares are held by institutional investors. 36.8% of iRadimed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current recommendations for Sysmex and iRadimed, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sysmex | 0 | 2 | 1 | 0 | 2.33 |
| iRadimed | 0 | 1 | 3 | 1 | 3.00 |
iRadimed has a consensus target price of $120.00, indicating a potential upside of 30.29%. Given iRadimed’s stronger consensus rating and higher probable upside, analysts plainly believe iRadimed is more favorable than Sysmex.
Profitability
This table compares Sysmex and iRadimed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sysmex | 7.13% | 7.28% | 5.24% |
| iRadimed | 27.36% | 24.48% | 21.25% |
Summary
iRadimed beats Sysmex on 13 of the 18 factors compared between the two stocks.
About Sysmex
Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.
About iRadimed
IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.
Receive News & Ratings for Sysmex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sysmex and related companies with MarketBeat.com's FREE daily email newsletter.
